Sign in
CompletedPhase 2/3

Intranasal Insulin to Prevent Intensive Care Unit Delirium

Key facts

Who runs it
Radboud University Medical Center
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
30 people enrolled
Started
30 Apr 2026
Ended
30 Jul 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Intranasal insulin-40U
  • Intranasal sodium chloride 0.9%
Record updated
3 August 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥65 years
  • Planned surgical admission to the ICU of the Radboudumc following complex cardiac surgery with CPB. Complex cardiac surgery is defined as all cardiac on-pump procedures except for isolated CABG
  • Able to receive intranasal spray (no obstructive nasal pathology precluding administration)
  • Informed consent from patient

Who cannot take part

  • Contra-indication for nasal administration (severe nasal pathology, recent nasal/sinus surgery, active epistaxis, active rhinitis, obstruction of either one or both nostrils)
  • Participating in other investigational medication trial
  • Non-complex or off-pump cardiac surgery
  • Known allergy/hypersensitivity to insulin or formulation excipients
  • Delirium at hospital admission

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to assess the feasibility, tolerability, and exploratory efficacy of intranasal insulin to prevent delirium in ICU patients aged ≥65 years after complex elective cardiac surgery with cardiopulmonary bypass

The 2 groups in the trial

  • Intranasal insulinTreatment being tested

    Intranasal insulin administered twice daily. Each administration consists of two sprays of 10 IU (0.1 ml) in alternating nostrils, totalling to 40 IU per day.

    Treatment: Intranasal insulin-40U

  • Intranasal placebo (NaCl 0.9%)Placebo, for comparison

    Intranasal placebo (sodium chloride 0.9%) administered twice daily. Each administration consists of two sprays of 0.1 ml in alternating nostrils, totalling to 0.4 mL per day.

    Treatment: Intranasal sodium chloride 0.9%

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Intranasal Insulin for the Prevention of Delirium in ICU Patients Undergoing Elective Cardiac Surgery: a Randomized, Double-blind, Placebo-controlled Pilot Trial (INSPIRE)
Record updated
3 August 2026